Jun 20 |
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
Jun 20 |
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
|
Jun 13 |
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
|
May 28 |
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
|
May 22 |
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
|
May 20 |
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
|
May 6 |
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
|
Mar 11 |
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
|
Feb 29 |
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
|
Feb 14 |
Sonnet BioTherapeutics GAAP EPS of -$0.31, revenue of $18.63M
|